Clinical journal of oncology nursingHumansMaleOncology NursingLutetiumHeterocyclic Compounds
Managing Prostate Cancer During [177Lu]Lu-PSMA-617 Radioligand Therapy: Tips for Oncology Nurses.
Avery Spitz
Published: 202510.1188/25.CJON.S1.E28-E33
Abstract
BACKGROUND: Radioligand therapy (RLT), particularly lutetium 177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 is an approved targeted treatment for metastatic castration-resistant prostate cancer. OBJECTIVES: This article aims to equip onc…
Preview only. Read the full abstract at the source